Novartis’ Exjade gets committee review
Executive Summary
Novartis' oral iron chelator Exjade (deferasirox) will be reviewed for treatment of chronic iron overload during blood transfusions by FDA's Blood Products Advisory Committee on Sept. 29. Panel will likely discuss Exjade's failure to demonstrate non-inferiority to Novartis' current iron overload therapy Desferal in the pivotal study. The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m.[Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com or call 800-627-8171.]...
You may also be interested in...
Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector
Novartis will continue to focus on the cardiovascular-metabolic segment in the near term with filings planned for new diabetes and hypertension therapies and line-extensions for its existing agents
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.